¿Cómo debe evaluarse y manejarse la ginecomastia?

1. Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab 1979;48:338-40.
2. Ley SJ. Cardiac surgery in an era of antiplatelet therapies: generating new evidence. Reflect Nurs Leadersh 2002;28(2):35.
3. Carlson HE. Gynecomastia. N Engl J Med 1980;303:795-9.
4. Niewoehner CB, Nuttal FQ. Gynecomastia in a hospitalized male population Am J Med 1984;77:633-8.
5. Georgiadis E, Papandreou L, Evangelopoulou C, et al. Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol 1994;21:579-87.
6. Williams MJ. Gynecomastia: its incidence, recognition and host characterization in 447 autopsy cases. Am J Med 1963;34:103-12.
7. Andersen JA, Gram JB. Gynecomasty: histological aspects in a surgical material. Acta Pathol Microbiol Immunol Scand [A] 1982;90:185-90.
8. Bannayan GA, Hajdu SI. Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol 1972;57:431-7.
9. Nicolis GL, Modlinger RS, Gabrilove JL. A study of the histopathology of human gynecomastia. J Clin Endocrinol Metab 1971;32:173-8.
10. Mathur R, Braunstein GD. Gynecomastia: pathomechanisms and treatment strategies. Horm Res 1997;48:95-102.
11. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86:724-31.
12. Braunstein GD. Aromatase and gynecomastia. Endocr Relat Cancer 1999;6:315-24.
13. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678-87.
14. Evans GF, Anthony T, Turnage RH, et al. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg 2001;181:96-100. [Erratum, Am J Surg 2001;181:579.]
15. Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy 1993;13:37-45.
16. García Rodríguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994;308:503-6. [Erratum, BMJ 1994;308:819.]
17. Sauer MA, Rifka SM, Hawks RL, Cutler GB Jr, Loriaux DL. Marijuana: interaction with the estrogen receptor. J Pharmacol Exp Ther 1983;224:404-7.
18. Finkelstein JS, McCully WF, MacLaughlin DT, Godine JE, Crowley WF Jr. The mortician’s mystery: gynecomastia and reversible  hypogonadotropic hypogonadism in an embalmer. N Engl J Med 1988;318:961-5.
19. Brody SA, Loriaux DL. Epidemic of gynecomastia among Haitian refugees: exposure to an environmental antiandrogen. Endocr Pract 2003;9:370-5.
20. Rahim S, Ortiz O, Maslow M, Holzman R. A case-control study of gynecomastia in HIV-1-infected patients receiving HAART. AIDS Read 2004;14:23-4,29-32, 35-40.
21. Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007;356:479-85.
22. Di Lorenzo G, Autorino R, Perdonà S, De Placido S. Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncol 2005;6:972-9.
23. Satoh T, Fujita KI, Munakata H, et al. Studies on the interactions between drugs and estrogen: analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPHcytochrome P450 reductase. Anal Biochem 2000;286:179-86.
24. Satoh T, Munakata H, Fujita K, et al. Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17. Biol Pharm Bull 2003;26:695-700.
25. Satoh T, Tomikawa Y, Takanashi K, Itoh S, Itoh S, Yoshizawa I. Studies on the interactions between drugs and estrogen. III. Inhibitory effects of 29 drugs reported to induce gynecomastia on the glucuronidation of estradiol. Biol Pharm Bull 2004;27:1844-9.
26. Ersöz HO, Önde ME, Terekeci H, Kurtoglu S, Tor H. Causes of gynaecomastia in young adult males and factors associated with idiopathic gynaecomastia. Int J Androl 2002;25:312-6.
27. Dejager S, Bry-Gauillard H, Bruckert E, et al. A comprehensive endocrine description of Kennedy’s disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002;87:3893-901.
28. Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med 2003;348:1855-65.
29. Irving LM, Wall M, Neumark-Sztainer D, Story M. Steroid use among adolescents: findings from Project EAT. J Adolesc Health2002;30:243-52.
30. Braunstein GD. Gynecomastia. N Engl J Med 1993;328:490-5.
31. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Societyposition statement. J Clin Endocrinol Metab 2007;92:405-13.
32. Rohrich RJ, Ha RY, Kenkel JM, Adams WP Jr. Classification and management of gynecomastia: defining the role of ultrasound-assisted liposuction. Plast Reconstr Surg 2003;111:909-23.
33. Tashkandi M, Al-Qattan MM, Hassanain JM, Hawary MB, Sultan M. The surgical management of high-grade gynecomastia. Ann Plast Surg 2004;53:17-20.
34. Treves N. Gynecomastia; the origins of mammary swelling in the male: an analysis of 406 patients with breast hypertrophy, 525 with testicular tumors, and 13 with adrenal neoplasms. Cancer 1958;11:1083-102.
35. Gruntmanis U, Braunstein GD. Treatment of gynecomastia. Curr Opin Investig Drugs 2001;2:643-9.
36. Eversmann T, Moito J, von Werder K. Testosterone and estradiol levels in male gynecomastia: clinical and endocrine findings during treatment with tamoxifen. Dtsch Med Wochenschr 1984;109:1678-82. (In German.)
37. Parker LN, Gray DR, Lai MK, Levin ER. Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism 1986;35:705-8.
38. Alagaratnam TT. Idiopathic gynecomastia treated with tamoxifen: a preliminary report. Clin Ther 1987;9:483-7.
39. König R, Schönberger W, Neumann P, Benes P, Grimm W. Treatment of marked gynecomastia in puberty with tamoxifen. Klin Padiatr 1987;199:389-91. (In German.)
40. McDermott MT, Hofeldt FD, Kidd GS. Tamoxifen therapy for painful idiopathic gynecomastia. South Med J 1990;83:1283-5.
41. Staiman VR, Lowe FC. Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology 1997;50:929-33.
42. Ting ACW, Chow LWC, Leung YF. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia Am Surg 2000;66:38-40.
43. Khan HN, Rampaul R, Blamey RW. Management of physiological gynaecomastia with tamoxifen. Breast 2004;13:61-5.
44. Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 2004;145:71-6.
45. Hanavadi S, Banerjee D, Monypenny IJ, Mansel RE. The role of tamoxifen in the management of gynaecomastia. Breast 2006;15:276-80.
46. Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:4428-33.
47. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23:808-15.
48. Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozol e. Prostate Cancer Prostatic Dis 2005;8:75-83.
49. Perdonà S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005;6:295-300.
50. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other  roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-82.
51. Bowers SP, Pearlman NW, McIntyre RC Jr, Finlayson CA, Huerd S. Cost-effective management of gynecomastia. Am J Surg 1998;176:638-41.
52. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-76.